Gallium-68 somatostatin receptor PET/CT: Is it time to replace 111Indium DTPA octreotide for patients with neuroendocrine tumors?
- 6 May 2012
- journal article
- Published by Springer Science and Business Media LLC in Endocrine
- Vol. 42 (1), 3-4
- https://doi.org/10.1007/s12020-012-9681-4
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Diagnostic performance of Gallium-68 somatostatin receptor PET and PET/CT in patients with thoracic and gastroenteropancreatic neuroendocrine tumours: a meta-analysisEndocrine, 2012
- Molecular Theranostics: A Primer for the Imaging ProfessionalAmerican Journal of Roentgenology, 2011
- Gastroenteropancreatic neuroendocrine tumoursThe Lancet Oncology, 2008
- 68Ga-DOTA-Tyr3-Octreotide PET in Neuroendocrine Tumors: Comparison with Somatostatin Receptor Scintigraphy and CTJournal of Nuclear Medicine, 2007
- Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals?European Journal of Nuclear Medicine and Molecular Imaging, 2007
- Evaluation of the pharmacokinetics of 68Ga-DOTATOC in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapyEuropean Journal of Nuclear Medicine and Molecular Imaging, 2006
- Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targetingEuropean Journal of Nuclear Medicine and Molecular Imaging, 2003
- Evaluation of Positron Emission Tomography Imaging Using [68Ga]-DOTA-D Phe1-Tyr3-Octreotide in Comparison to [111In]-DTPAOC SPECT. First Results in Patients with Neuroendocrine TumorsMolecular Imaging & Biology, 2003
- Somatostatin receptor scintigraphy with [111In-DTPA-d-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patientsEuropean Journal of Nuclear Medicine and Molecular Imaging, 1993